Revvity, Inc. ( RVTY ) Nowojorska Giełda Papierów Wartościowych

Cena: 99.5 ( 3.51% )

Aktualizacja 07-23 21:58
Nowojorska Giełda Papierów Wartościowych
Branża: Medical - Diagnostics & Research

Notowania:


Informacje o spółce:
Sektor: Zdrowie
Branża: Medical - Diagnostics & Research
Zatrudnienie: 11 000
Giełda: Nowojorska Giełda Papierów Wartościowych
Ilość akcji w obrocie: 99.6078
Ilość akcji: Brak danych
Debiut giełdowy: 1965-07-06
WWW: https://www.perkinelmer.com
CEO: Dr. Prahlad R. Singh Ph.D.
Adres: 940 Winter Street
Siedziba: 02451 Waltham
ISIN: US7140461093
Opis firmy:

Revvvity, Inc. zapewnia produkty, usługi i rozwiązania dla rynków diagnostyki, nauk przyrodniczych i usług stosowanych na całym świecie. Działa w dwóch segmentach, roztworach odkrywania i analitycznych oraz diagnostyce. Segment Discovery & Analytical Solutions zapewnia instrumenty, odczynniki, informatykę, oprogramowanie, subskrypcje, wykrywanie i technologie obrazowania, które umożliwiają naukowcom poprawę przełomów badań na rynku badań nauk przyrodniczych, a także badań kontraktowych i usług laboratoryjnych. Zapewnia również technologie analityczne, rozwiązania i usługi dla swoich klientów, aby zrozumieć charakterystykę zdrowia różnych aspektów, w tym powietrza, wody i gleby. Ponadto ten segment oferuje rozwiązania dla rolników i producentów żywności; oraz oprzyrządowanie analityczne dla rynku przemysłowego, w tym przemysł chemiczny, półprzewodnikowy i elektroniczny, energetyka, smar, petrochemiczny i polimerowy. Segment diagnostyki zapewnia instrumenty, odczynniki, platformy testowe i oprogramowanie do wczesnego wykrywania zaburzeń genetycznych, takich jak ciąża i wczesne dzieciństwo, a także testy chorób zakaźnych na rynku diagnostycznym. Jego produkty są wykorzystywane do testowania i badań nad nieprawidłowościami genetycznymi, zaburzeniami i chorobami, w tym zespołu Downa, niedoczynności tarczycy, dystrofii mięśniowej, niepłodności i różnych stanów metabolicznych. Ten segment opracowuje również technologie, które umożliwiają i wspierają genomowe przepływy pracy za pomocą sekwencjonowania DNA sprzężonego z białkiem i nowej generacji do zastosowań w onkologii, immunodiagnostyce i odkrywaniu leków. Obsługuje firmy farmaceutyczne i biotechnologiczne, laboratoria, instytucje akademickie i badawcze, władze zdrowia publicznego, prywatne organizacje opieki zdrowotnej, lekarze i agencje rządowe. Firma była wcześniej znana jako Perkinelmer, Inc. i zmieniła nazwę na Revvity, Inc. w kwietniu 2023 r. Revvvity, Inc. został założony w 1937 roku i ma siedzibę w Waltham, Massachusetts.

Wskaźniki finansowe
Kapitalizacja (USD) 11 728 065 000
Aktywa: 12 769 737 000
Cena: 99.5
Wskaźnik Altman Z-Score: 2.9
Umiarkowany (ryzyko bankructwa średnie)
Dywidenda: 0
P/E: 41.1
Ilość akcji w obrocie: 100%
Średni wolumen: 1 207 803
Ilość akcji 117 870 000
Wskaźniki finansowe
Przychody TTM 2 721 555 000
Zobowiązania: 4 848 036 000
Przedział 52 tyg.: 87.7 - 129.5
Piotroski F-Score: 8
Silny (dobra jakość finansowa)
EPS: 2.4
P/E branży: 30.3
Beta: 1.056
Raport okresowy: 2025-07-28
WWW: https://www.perkinelmer.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Mr. Joel S. Goldberg Senior Vice President of Administration, General Counsel & Secretary 720 742 1969
Mr. Maxwell Krakowiak Senior Vice President & Chief Financial Officer 631 111 1990
Mr. Tajinder S. Vohra Senior Vice President of Global Operations 574 075 1966
Ms. Miriame Victor Senior Vice President & Chief Commercial Officer 555 397 1982
Dr. Prahlad R. Singh Ph.D. Chief Executive Officer, President & Director 1 434 579 1965
Mr. Stephen Barr Willoughby Senior Vice President of Investor Relations & Head of ESG 0 0
Ms. Magali Four Senior Vice President and Chief People & Culture Officer 0 0
Mr. Bryan A. Kipp Senior Vice President of Technology & Licensing 0 0
Mr. Andrew Okun Vice President, Chief Accounting Officer & Treasurer 0 1970
Ms. Madhuri Hegde FACMG, Ph.D. Senior Vice President & Chief Scientific Officer 0 0
Lista ETF z ekspozycją na akcje Revvity, Inc.
Symbol ETF Ilość akcji Wartość
SCHI 3 990 000 3 453 981
VOO 3 461 363 312 976 442
VB 3 030 228 273 993 215
VBR 1 948 251 176 160 855
RSP 1 490 638 151 016 535
IVV 1 439 725 142 115 236
SPY 1 425 234 141 309 105
TCAF 835 884 84 340 695
XLV 818 717 82 637 433
VDCP.L 751 000 593 007
VUCP.DE 751 000 505 064
VGPA.L 751 000 593 007
VDPA.L 751 000 593 007
VCPA.L 751 000 436 305
VUCE.DE 751 000 505 064
VUCP.L 751 000 436 305
VECA.DE 600 000 594 872
VECP.L 600 000 513 761
VECP.DE 600 000 594 872
VECA.L 600 000 513 761
IWR 431 099 42 553 745
VHT 375 713 33 971 969
CSPX.AS 289 846 28 610 653
CSP1.L 289 846 28 610 653
GSPX.L 289 846 28 610 653
SXR8.DE 289 846 28 610 653
CSSPX.MI 289 846 28 610 653
CSPX.L 289 846 28 610 653
IWD 275 381 27 182 891
SCHJ 270 000 253 960
SPHQ 207 829 21 055 155
VAGP.L 205 000 173 670
VAGS.L 205 000 173 670
IVE 193 111 19 061 983
IWS 179 625 17 730 769
SCHG 178 719 18 099 943
IWLE.DE 177 471 17 518 119
IWDA.L 177 471 17 518 119
IWDD.AS 177 471 17 518 119
IWDA.AS 177 471 17 518 119
EUNL.DE 177 471 17 518 119
SWDA.L 177 471 17 518 119
SWDA.MI 177 471 17 518 119
IWDG.L 177 471 17 518 119
V3GP.L 175 000 164 543
V3GS.L 175 000 164 543
SPLG 169 407 16 547 486
VUAA.MI 165 346 12 733 413
VUSA.MI 165 346 12 733 413
VUSD.L 165 346 14 950 585
VUSA.DE 165 346 12 733 413
VUAA.L 165 346 14 950 585
VUSA.L 165 346 10 999 893
VUSA.AS 165 346 12 733 413
EDMU.DE 163 196 16 109 100
EDMU.SW 163 196 16 109 100
OM3L.DE 163 196 16 109 100
EEDG.L 163 196 16 109 100
EEDS.L 163 196 16 109 100
CBUC.DE 163 196 16 109 100
HEAL.L 150 536 14 859 441
2B78.DE 150 536 14 859 441
DRDR.L 150 536 14 859 441
GCOR 150 000 137 321
SPYV 131 707 13 030 796
RSPH 125 094 12 673 273
SCHX 118 057 11 960 354
IUSV 97 786 9 652 411
EWSP.L 94 231 9 301 542
ISPE.L 94 231 9 301 542
IWB 88 709 8 756 425
FXH 82 970 8 189 968
JHMM 75 736 7 459 996
SUWU.SW 69 309 6 841 464
SUSW.L 69 309 6 841 464
2B7J.DE 69 309 6 841 464
SGWS.L 69 309 6 841 464
SUWS.L 69 309 6 841 464
SUWG.L 69 309 6 841 464
SCWS.SW 69 309 6 841 464
2B7K.DE 69 309 6 841 464
IXJ 67 248 6 638 033
IYH 66 276 6 542 093
VONV 65 180 5 893 575
DON 64 951 6 074 867
VWRL.L 59 240 3 941 030
VWRP.L 59 240 3 941 030
VWCE.DE 59 240 4 562 114
VWRD.L 59 240 5 356 480
VGWL.DE 59 240 4 562 114
VWRL.AS 59 240 4 562 114
IHCU.L 56 488 5 575 899
IUHC.L 56 488 5 575 899
IUHE.AS 56 488 5 575 899
QDVG.DE 56 488 5 575 899
FHLC 51 614 5 207 852
FNDX 51 011 5 167 924
IUSA.L 45 200 4 461 692
IDUS.L 45 200 4 461 692
IUSA.DE 45 200 4 461 692
IUSA.AS 45 200 4 461 692
SUAS.L 40 004 3 948 759
36B6.DE 40 004 3 948 759
3SUR.DE 40 004 3 948 759
SUUS.L 40 004 3 948 759
QDVR.DE 40 004 3 948 759
SUAP.L 40 004 3 948 759
SRIL.AS 40 004 3 948 759
LQQ.PA 36 797 3 684 483
ACWI 35 076 3 462 370
TMSL 33 296 3 359 566
IWV 32 484 3 206 461
GPSA.L 32 427 3 200 889
SASU.L 32 427 3 200 889
SLUS.DE 32 427 3 200 889
SGAS.DE 32 427 3 200 889
SDUS.L 32 427 3 200 889
SAUA.MI 32 427 3 200 889
ISAC.L 32 273 3 185 692
IUSQ.DE 32 273 3 185 692
SSAC.L 32 273 3 185 692
EUSA 29 861 2 947 614
VOOV 28 281 2 557 168
ESGV 26 356 2 788 464
PABU 24 893 2 457 188
PRF 23 954 2 426 779
SPTM 23 873 2 356 456
BBCB 23 000 19 689
IMCG 22 678 2 238 545
FTA 20 600 2 033 426
XSP.TO 19 963 2 688 399
VONE 18 800 1 699 896
PBUS 17 764 1 799 670
IUSE.L 16 360 1 614 887
IBCF.DE 16 360 1 614 887
IVV.AX 16 311 2 471 496
XUS.TO 15 120 2 036 191
IXJ.AX 14 796 2 241 870
PINK 14 426 1 455 583
EEWG.L 14 264 1 408 006
EGMW.L 14 264 1 408 006
EMND.DE 14 264 1 408 006
EDMW.DE 14 264 1 408 006
EEWD.L 14 264 1 408 006
VEVE.L 12 786 850 608
VGVE.DE 12 786 984 658
VGVF.DE 12 786 984 658
VHVE.L 12 786 1 156 110
VDEV.L 12 786 1 156 110
FEX 12 209 1 205 150
IMCB 11 806 1 165 368
BBUS 11 165 1 079 878
IUSF.L 11 054 1 091 108
IUSZ.L 11 054 1 091 108
QDVC.DE 11 054 1 091 108
JPME 10 759 1 040 610
SNAW.DE 10 651 1 051 395
SDWD.L 10 651 1 051 395
SAWD.L 10 651 1 051 395
S6DW.DE 10 651 1 051 395
IMCV 9 472 934 989
VTHR 9 442 853 745
RWL 9 152 927 189
VNRT.DE 9 119 702 260
VNRG.L 9 119 606 655
VNRA.L 9 119 824 539
VNRT.L 9 119 606 655
VNRA.DE 9 119 702 260
VDNR.L 9 119 824 539
SCHK 8 878 858 680
SPXL 8 781 886 002
KOMP 8 547 841 881
CFA 8 403 851 307
URTH 8 384 827 601
PTLC 7 678 777 858
XYLD 7 295 730 448
USXF 7 146 705 421
SIZE 7 088 699 646
IWDE.L 6 764 667 716
IBCH.DE 6 764 667 716
JPUS 6 761 653 923
CFO 6 640 672 698
ONEV 6 572 651 871
XHC.TO 5 998 807 707
EQAL 5 981 605 935
JVAL 5 633 544 823
RSPA 5 600 567 336
XUU.TO 5 569 763 691
XEQT.TO 5 484 738 589
IYY 5 373 530 357
SPYX 5 242 515 661
ISWD.L 4 915 485 173
ISWD.SW 4 915 485 173
ISDW.L 4 915 485 173
CBUI.DE 4 869 480 614
CSUS.L 4 854 479 094
SXR4.DE 4 854 479 094
CU1.L 4 854 479 094
CSUS.SW 4 854 479 094
SPUS 4 838 490 137
JHML 4 773 470 140
ILCG 4 485 442 724
IWFS.L 4 259 420 436
IWSZ.L 4 259 420 436
IS3T.DE 4 259 420 436
GUSA 4 055 410 812
SUSL 3 985 403 720
IHVV.AX 3 913 592 874
WPAB.AS 3 909 385 889
WPAB.SW 3 909 385 889
WPAD.AS 3 909 385 889
EFIV 3 660 364 196
EUNA.DE 3 536 298 716
QVML 3 443 348 810
PEXL 3 434 347 898
HLAL 3 154 317 765
ILCV 3 092 305 247
PTL 3 029 306 867
IDNA.L 2 961 292 279
INAA.L 2 961 292 279
INAA.SW 2 961 292 279
IQQN.DE 2 961 292 279
GINN 2 942 298 054
XAW.TO 2 903 390 937
ISDU.L 2 671 263 608
ISUS.L 2 671 263 608
WHCA.AS 2 620 258 644
CBUF.DE 2 620 258 644
WHCS.AS 2 620 258 644
IWLD.AX 2 537 384 415
CURE 2 471 249 323
ILCB 2 416 238 483
FNDB 2 353 227 582
GPIX 2 343 237 369
UPAD.L 2 280 225 009
UPAB.AS 2 280 225 009
MODL 2 241 227 035
IWDC.SW 2 149 212 080
IGUS.L 2 128 210 083
ESPX.AS 2 079 205 254
CBUM.DE 2 079 205 254
QDPL 2 069 209 610
TILT 2 015 201 761
STRV 1 977 200 289
QUS 1 892 186 658
DTD 1 797 168 073
IUSC.SW 1 749 172 687
LSK8.DE 1 700 170 221
BXX.PA 1 700 170 221
V3AL.L 1 697 153 442
V3AA.L 1 697 153 442
CRBN 1 640 161 893
GVUS 1 543 156 321
SZNE 1 504 152 370
EPS 1 481 138 517
XWD.TO 1 449 199 633
IHWL.AX 1 414 214 254
XUSR.TO 1 359 183 023
FCTR 1 307 129 013
XVV 1 043 105 666
NZAC 968 95 599
SPYI 964 97 662
FAB 958 94 564
MFUS 929 89 852
VLU 902 89 346
SSPX 875 88 646
HCMT 859 86 673
XUH.TO 795 78 516
R1VL.L 774 76 401
SAWI.AS 667 65 851
CBUY.DE 667 65 851
IGWD.L 634 62 601
STXV 462 46 805
TOK 413 40 726
MDEV 400 39 484
SPUU 369 37 232
PBP 334 33 837
GEQT.TO 295 39 764
ONOF 286 28 637
ONEO 270 26 609
GGRO.TO 261 35 128
ESG 231 23 130
IHCB.AX 210 31 367
XTR.TO 190 17 963
GBAL.TO 172 23 162
XYLG 145 14 518
PHDG 140 14 183
STXG 118 11 954
QWLD 116 11 462
MMTM 112 11 039
XRMI 104 10 413
XMAG 103 10 434
XSC.TO 52 4 818
INRO 48 4 695
GCNS.TO 36 4 897
NZUS 27 2 674
XCLR 9 901
XTR 5 500
PXS.TO 0 0
VCEB 0 252 702
ESG.TO 0 0
EQL.TO 0 0
IE00BN4Q0370.SG 0 0
VTC 0 206 824
VPLS 0 1 880
VTC 0 304 179
FTLS -25 454 0
Wiadomości dla Revvity, Inc.
Tytuł Treść Źródło Aktualizacja Link
Revvity Wins Permanent Injunction Enforcing Agreements with Cloud Software Group WALTHAM, Mass.--(BUSINESS WIRE)--Today, Revvity, Inc. (NYSE: RVTY) announced that the Massachusetts Superior Court has ruled in its favor and will issue a permanent injunction to enforce Revvity's rights under its agreements with Cloud Software Group (CSG) related to the Spotfire® software. This ruling follows a preliminary injunction issued in April 2024, which will become permanent, ensuring uninterrupted access to Spotfire software and support for Revvity and its customers, protecting operat. businesswire.com 2025-02-20 14:30:00 Czytaj oryginał (ang.)
Revvity to Present at Upcoming Investor Conferences WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences in March 2025: 46th Annual Raymond James Institutional Investor Conference Monday, March 3, 2025 7:30 a.m. ET - Max Krakowiak, senior vice president and chief financial officer TD Cowen 45th Annual Health Care Conference Tuesday, March 4, 2025 9:10 a.m. ET - Prahlad Singh, president and chief executive officer Leerink Partners Global Healthcare Conference Tuesday, M. businesswire.com 2025-02-20 10:00:00 Czytaj oryginał (ang.)
Molecular Infectious Disease Testing Market to Hit USD 17.78 Billion by 2029 with 13.7% CAGR | MarketsandMarkets™. DELRAY BEACH, Fla., Feb. 13, 2025 /PRNewswire/ -- The global Molecular Infectious Disease Testing market, valued at US$8.49 billion in 2023, is forecasted to grow at a robust CAGR of 13.7%, reaching US$9.37 billion in 2024 and an impressive US$17.78 billion by 2029. Major drivers of market growth include rising burden of infectious diseases and rapid technological advancements in molecular diagnostics. The increased incidence of emerging infectious diseases and antibiotic-resistant infections leads to greater demand for accurate and reliable diagnostics. In addition, there are rapid advances in the efficiency of molecular testing techniques, such as PCR and next-generation sequencing, which have improved diagnostic capabilities. These provide results that are more sensitive and at a faster speed, and allow for the simultaneous identification of multiple pathogens, which becomes vital in handling complex and continually changing infectious disease threats. These are some of the major contributors to the growing market. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=40667482 Browse in-depth TOC on "Molecular Infectious Disease Testing Market" 539 - Tables61 - Figures448 - Pages An advancement in multiplex testing which could transform the molecular infectious disease testing market, is the integrated, fully automated multiplex diagnostic platforms. It will combine testing for multiple pathogens in a single reaction with the advantage of full automation, right from sample preparation to result interpretation. The automation of multiplex testing minimizes the chance of human error, enhances throughput, and accelerates the diagnostic process. These are the factors why this technology will thrive in environments of high demand such as hospitals, urgent care centers, and public health labs. The more these systems become user-friendly and affordable, the greater their potential will be to enhance access to multiplex tests in more rapid and comprehensive infectious disease surveillance and management across a range of healthcare settings. Based on product & service, the global molecular infectious disease testing market has been segmented into reagents & kits, instruments, and services & software. The fastest-growing segment within the molecular infectious disease testing market is the reagents and kits, mainly due to their critical role in making it possible for an accurate and efficient diagnosis. The growing use of molecular testing in clinical practices has caused the demand for good quality reagents and kits since they are indispensable in PCR, next-generation sequencing, and other molecular assays. The expansion of testing volumes within diagnostic laboratories and hospitals further propels the growth. Moreover, increased accessibility to ready-to-use, standardized kits and reagents that enhance sensitivity and reduce the turnaround time accelerate their demand in the molecular infectious disease testing market. Categorized by type, the molecular infectious disease testing market is segmented into single plex testing and multiplex testing. The multiplex testing segment is expected to witness the highest growth rate in the molecular infectious disease testing market because of its ability to test for more than one pathogen in a single test. Such capability can considerably reduce the testing time and cost while improving efficiency and accuracy of diagnostics. This is very helpful in complex infections, which could be due to multiple pathogens. The increasing demand for this type of testing in healthcare settings having high patient numbers is further due to the need for comprehensive, timely diagnostic solutions. Technological advancements in multiplex assay platforms have made this testing become indispensable in improving the clinical outcome, enhancing infection control measures. Key players in the molecular infectious disease testing market include Danaher (US), F. Hoffmann- La Roche Ltd (Switzerland), bioMérieux (France), Hologic, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), Revvity (US), Siemens Healthineers AG (Germany), BD (US), Grifols, S.A. (Spain), DiaSorin S.p.A. (Italy), and Seegene Inc. (South Korea). These companies have a diversified product portfolio and a good geographic presence also. With growing global burden of infectious diseases and increasing need for accurate diagnostics, such players are well-positioned to develop novel diagnostic technologies and further expand their offerings. They expand their market share through subsidiaries across the world based on the strength of their R&D capabilities and diversified product and services portfolios. Their product launches, agreements, acquisitions, and partnerships further enhance their portfolio while expanding the reach of their global business. Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=40667482 The key players operating in this market are Danaher (US), F. Hoffmann-La Roche Ltd (Switzerland), bioMérieux (France), Hologic, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), Revvity (US), Siemens Healthineers AG (Germany), BD (US), Grifols, S.A. (Spain), DiaSorin S.p.A. (Italy), and Seegene Inc. (South Korea). The market players have adopted several strategies such as advanced product development, partnerships, expansions, and acquisitions to strengthen their market position. The organic and inorganic strategies have allowed the market players to expand across geographies through the provision of advanced molecular infectious disease tests. Danaher emerged as the leader in the molecular infectious disease testing market in 2023. Its position as the leader in the market across the US serves as a platform from where it can penetrate more into the developing economies and build its global presence across more geographies. The company is also responsible for innovation in its products to cater to the varied needs of customers worldwide. This has assisted the company in building on its leadership position in the market. Additionally, the company also adopts certain organic growth strategies by launching new products and seeking relevant regulatory clearances. For example, in March 2024, the US FDA cleared the Xpert Xpress GBS test. In November 2022, it launched the Xpert Xpress MVP, a multiplexed PCR test. Such strategic steps have helped the company stay continuously in the lead in the molecular infectious disease testing market. F. Hoffmann-La Roche Ltd is a significant global player in the molecular infectious disease testing market. Its broad portfolio and presence in all parts of the world have helped it sustain its competitive advantage. Roche has a very good direct and indirect distribution network around the world, which enables it to balance out demand fluctuations in the different markets. Its strategic emphasis on organic as well as inorganic growth strategies makes the company stronger in the marketplace. For example, in September 2024, Roche launched the cobas Respiratory flex test. This is the first test by Roche using Roche's innovative and proprietary TAGS (Temperature-Activated Generation of Signal) technology. This technology identifies as many as 15 pathogens in a single PCR test by using multiplex polymerase chain reaction testing combined with color, temperature, and data processing. All these strategies, coupled with its strong presence in the market, have given Roche further opportunities to enhance its position within the molecular infectious disease testing market. bioMérieux is a prominent player in the molecular infectious disease testing market. Its robust position in the market is due to extensive distribution networks in America, Europe, the Middle East & Africa, and Asia Pacific. High investment in research & development, coupled with organic growth strategies, also helps bioMérieux strengthen its position in the market. Such initiatives include the launching of products and gaining appropriate regulatory approvals in order to extend its market shares. In December 2024, bioMérieux announced that the company's BIOFIRE FILMARRAY Tropical Fever (TF) Panel has achieved USD FDA Special 510(k) clearance. This new, innovative PCR-based testing solution brings fast and accurate pathogen identification in patients suffering from unexplained fever to clinicians, optimizing the treatment overall. For more information, Inquire Now! Related Reports: Molecular Diagnostics Market Veterinary Diagnostics Market Molecular Quality Controls Market IVD Contract Manufacturing Market Genetic Testing Market Get access to the latest updates on Molecular Infectious Disease Testing Companies and Molecular Infectious Disease Testing Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes. The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry. To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress Ave.Suite 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: [email protected]Visit Our Website: https://www.marketsandmarkets.com/ Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg https://www.prnewswire.com 2025-02-13 12:05:00 Czytaj oryginał (ang.)
RVTY Q4 Earnings Beat Estimates, Sales Miss, Segments Robust Revvity's fourth-quarter results showcase strong growth in Diagnostics business, along with recovery in Life Sciences segmental sales. zacks.com 2025-01-31 16:15:24 Czytaj oryginał (ang.)
Revvity (RVTY) Reports Q4 Earnings: What Key Metrics Have to Say While the top- and bottom-line numbers for Revvity (RVTY) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. zacks.com 2025-01-31 12:35:34 Czytaj oryginał (ang.)
Revvity, Inc. (RVTY) Q4 2024 Earnings Call Transcript Revvity, Inc. (NYSE:RVTY ) Q4 2024 Earnings Conference Call January 31, 2025 8:00 AM ET Company Participants Steve Willoughby - Senior Vice President, Investor Relations Prahlad Singh - President & Chief Executive Officer Max Krakowiak - Senior Vice President & Chief Financial Officer Conference Call Participants Doug Schenkel - Wolfe Research Vijay Kumar - Evercore ISI Patrick Donnelly - Citi Michael Ryskin - Bank of America Puneet Souda - Leerink Partners Matt Sykes - Goldman Sachs Luke Sergott - Barclays Andrew Cooper - Raymond James Catherine Schulte - Baird Dan Brennan - TD Cowen Operator Hello, everyone, and welcome to Revvity's Fourth Quarter 2024 Earnings Call. My name is Lydia, and I will be your operator today. seekingalpha.com 2025-01-31 11:34:22 Czytaj oryginał (ang.)
Revvity (RVTY) Surpasses Q4 Earnings Estimates Revvity (RVTY) came out with quarterly earnings of $1.42 per share, beating the Zacks Consensus Estimate of $1.36 per share. This compares to earnings of $1.25 per share a year ago. zacks.com 2025-01-31 10:11:26 Czytaj oryginał (ang.)
Revvity forecasts 2025 revenue, profit below estimates amid weak biotech spending Medical equipment maker Revvity forecast full-year profit and revenue for 2025 below Wall Street estimates on Friday, as it expects soft demand for its products and services used in drug research. reuters.com 2025-01-31 09:32:50 Czytaj oryginał (ang.)
Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2024 WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today reported financial results for the fourth quarter and full year ended December 29, 2024. Fourth Quarter 2024 The Company reported GAAP earnings per share of $0.78, as compared to $0.64 in the same period a year ago. GAAP revenue for the quarter was $729 million, as compared to $696 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $119 million, as compared to $77 million f. businesswire.com 2025-01-31 08:00:00 Czytaj oryginał (ang.)
Revvity Gears Up for Q4 Earnings: What's in the Offing? RVTY's fourth-quarter results are likely to reflect decent performance in the Diagnostics segment. The Life Sciences segment is likely to have faced continued challenges in China. zacks.com 2025-01-29 11:40:35 Czytaj oryginał (ang.)
Revvity (RVTY) Earnings Expected to Grow: Should You Buy? Revvity (RVTY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com 2025-01-24 13:06:11 Czytaj oryginał (ang.)
Will Revvity (RVTY) Beat Estimates Again in Its Next Earnings Report? Revvity (RVTY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. zacks.com 2025-01-23 15:16:36 Czytaj oryginał (ang.)
Revvity Ignites Scientific Breakthroughs at SLAS2025 WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. is set to unveil its groundbreaking new Phenologic.AI™ software at SLAS2025 in San Diego, January 27-29. Designed to redefine cellular imaging workflows for Revvity's Harmony™ and Signals Image Artist™ software packages, the Phenologic.AI software leverages pre-trained deep-learning models to analyze brightfield images, providing an additional multiplexing channel and streamlined workflows for live cell analysis. This significant advancement expand. businesswire.com 2025-01-23 10:00:00 Czytaj oryginał (ang.)
RVTY Stock Falls Despite FDA Nod for Automated Testosterone Test Revvity aims to expand the FDA-cleared menu for the EUROIMMUN family of ChLIA automation solutions to serve a wider patient pool. zacks.com 2025-01-13 12:55:34 Czytaj oryginał (ang.)
Revvity to Hold Earnings Call on Friday, January 31, 2025; Provides Update on Financial Performance WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its fourth quarter and full year 2024 financial results prior to market open on Friday, January 31, 2025. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available via this reg. businesswire.com 2025-01-12 19:00:00 Czytaj oryginał (ang.)
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now RVTY's strong product portfolio raises optimism about the stock. zacks.com 2024-12-31 11:45:40 Czytaj oryginał (ang.)
Revvity to Present at J.P. Morgan Healthcare Conference WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) will present at the 43rd annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 8:15 a.m. PT in San Francisco, CA. President and Chief Executive Officer Prahlad Singh will provide an update on the Company and its strategic priorities. To access the presentation, a live audio webcast will be available via this page. A replay of the presentation will be posted on the Revvity Investor Relations website after the event and. businesswire.com 2024-12-17 10:00:00 Czytaj oryginał (ang.)
Safe Biopharma: Revvity's Recurring Revenues And Diagnostics Revvity, Inc. is a leader in life sciences and diagnostics with diversified revenue streams and a strong balance sheet, making it a low-risk biopharma play. The company's recurring revenue base (80%) from consumables, services, and software ensures predictable income and financial stability. The company has a global footprint and an estimated TAM exceeding $60 billion, showcasing its significant market opportunity. seekingalpha.com 2024-12-16 02:27:51 Czytaj oryginał (ang.)
Why Is Revvity (RVTY) Down 8.7% Since Last Earnings Report? Revvity (RVTY) reported earnings 30 days ago. What's next for the stock? zacks.com 2024-12-04 14:36:36 Czytaj oryginał (ang.)
Revvity Broadens Relationship with Genomics England to Advance Genomics in the UK WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced an expansion of its work with Genomics England that leverages both organizations' expertise and resources to advance critical genomic initiatives across the United Kingdom. Building on the parties' long and productive work history, this advanced collaboration is dedicated to accelerating Genomics England's renowned research programs, supporting diverse areas in genomics, and fostering talent in innovative healthcare fi. businesswire.com 2024-11-20 10:00:00 Czytaj oryginał (ang.)
These Analysts Revise Their Forecasts On Revvity Following Q3 Results Revvity, Inc. RVTY reported better-than-expected third-quarter earnings on Monday. benzinga.com 2024-11-05 16:06:14 Czytaj oryginał (ang.)
RVTY Q3 Earnings & Revenues Beat Estimates, Guidance Revised Revvity's third-quarter results showcase strong growth in Diagnostics business, along with a decline in Life Sciences segmental sales. zacks.com 2024-11-04 15:40:18 Czytaj oryginał (ang.)
Revitty (RVTY) Q3 2024 Earnings Call Transcript Revitty Incorporated (NYSE:RVTY ) Q3 2024 Earnings Conference Call November 4, 2024 8:00 AM ET Company Participants Prahlad Singh - President, Chief Executive Officer Max Krakowiak - Senior Vice President, Chief Financial Officer Steve Willoughby - Head of Investor Relations Conference Call Participants Mike Ryskin - Bank of America Vijay Kumar - Evercore ISI Dan Leonard - UBS Andrew Cooper - Raymond James Luke Sergott - Barclays Dan Brennan - TD Cowen Puneet Souda - Leerink Partners Dan Arias - Stifel Matt Sykes - Goldman Sachs Brandon Couillard - Wells Fargo Patrick Donnelly - Citi Jack Meehan - Nephron Research Operator Hello everyone and welcome to Revitty's third quarter 2024 earnings conference call. My name is Lydia and I will be your Operator today. seekingalpha.com 2024-11-04 14:30:29 Czytaj oryginał (ang.)
Here's What Key Metrics Tell Us About Revvity (RVTY) Q3 Earnings Although the revenue and EPS for Revvity (RVTY) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com 2024-11-04 12:35:32 Czytaj oryginał (ang.)
Revvity (RVTY) Surpasses Q3 Earnings and Revenue Estimates Revvity (RVTY) came out with quarterly earnings of $1.28 per share, beating the Zacks Consensus Estimate of $1.13 per share. This compares to earnings of $1.18 per share a year ago. zacks.com 2024-11-04 10:11:23 Czytaj oryginał (ang.)
Revvity cuts 2024 revenue forecast amid biotech spending slowdown Revvity cut its 2024 revenue forecast as reduced biotech spending and a strong dollar weigh on demand for its tools and services used in drug development. reuters.com 2024-11-04 09:55:26 Czytaj oryginał (ang.)
Revvity Announces Financial Results for the Third Quarter of 2024 WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the third quarter ended September 29, 2024. The Company reported GAAP earnings per share of $0.77, as compared to $0.08 in the same period a year ago. GAAP revenue for the quarter was $684 million, as compared to $671 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $98 million, as compared to $69 million for the same period a year ago. GAA. businesswire.com 2024-11-04 08:00:00 Czytaj oryginał (ang.)
Revvity to Report Q3 Earnings: What's in Store for the Stock? RVTY third-quarter results are likely to reflect decent performance in the Diagnostics segment, while the Life Sciences segment is likely to face continued challenges in China. zacks.com 2024-11-01 16:16:10 Czytaj oryginał (ang.)
Earnings Preview: Revvity (RVTY) Q3 Earnings Expected to Decline Revvity (RVTY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com 2024-10-28 13:05:23 Czytaj oryginał (ang.)
Revvity Board Declares Quarterly Dividend WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of Revvity, Inc. (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on February 7, 2025 to all shareholders of record at the close of business on January 17, 2025. About Revvity At Revvity, “impossible” is inspiration, and “can't be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows fro. businesswire.com 2024-10-24 20:05:00 Czytaj oryginał (ang.)
Revvity Shares Decline Despite Launch of Transcribe AI Solution RVTY introduces Transcribe AI that digitizes handwritten test request forms, improving workflow speed and reducing manual data entry errors. zacks.com 2024-10-23 15:51:07 Czytaj oryginał (ang.)
Revvity Highlights its Strong Progress on Sustainability and Workplace Culture in 2024 Impact Report WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today unveils its annual Impact Report, a declaration of the Company's sustainability, social and governance strategy, initiatives and performance. The report showcases Revvity's continued evolution and strengthened commitments to creating a lasting, positive impact on the world. “Whether it's from developing groundbreaking solutions that drive positive health outcomes or through our sustainability initiatives, such as reducing waste a. businesswire.com 2024-10-22 12:00:00 Czytaj oryginał (ang.)
RVTY's Latest Launch to Enable APOE Genotyping of Alzheimer's Disease Revvity's latest solution for specific typing of AD-associated APOE gene is likely to allow assessment of a patient's risk for adverse effects from new anti-amyloid therapy for Alzheimer's. zacks.com 2024-10-10 15:00:41 Czytaj oryginał (ang.)
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now RVTY's continued focus on innovations and a strong product portfolio raise optimism about the stock. zacks.com 2024-10-07 16:35:33 Czytaj oryginał (ang.)
Reasons to Retain Revvity Stock in Your Portfolio for Now RVTY's strong product portfolio raises optimism about the stock. zacks.com 2024-09-06 14:01:26 Czytaj oryginał (ang.)